2024
Outcomes and Recurrence Rates Among Patients With Provoked and Cryptogenic Cerebral Venous Thrombosis
Al Kasab S, Almallouhi E, Shu L, Kicielinski K, Salehi Omran S, Liebeskind D, Zubair A, Vedovati M, Paciaroni M, Antonenko K, Heldner M, de Havenon A, Henninger N, Yaghi S. Outcomes and Recurrence Rates Among Patients With Provoked and Cryptogenic Cerebral Venous Thrombosis. Neurology Clinical Practice 2024, 15: e200381. PMID: 39399562, PMCID: PMC11464219, DOI: 10.1212/cpj.0000000000200381.Peer-Reviewed Original ResearchRisk of recurrent venous thromboembolismRecurrent venous thromboembolismCerebral venous thrombosisVenous thromboembolismFemale patientsVenous thrombosisBaseline characteristicsOutcome of cerebral venous thrombosisRate of recurrent venous thromboembolismProvoking factorsRare cause of strokeTransient provoking factorsKaplan-Meier survival analysisDuration of anticoagulationOutcomes of patientsMann-Whitney <i>Cause of strokeConsecutive patientsRare causeRecurrence rateMale patientsMulticenter studyRetrospective databaseStandard treatmentCox regression
2023
Trends in Venous Thromboembolism Readmission Rates after Ischemic Stroke and Intracerebral Hemorrhage
Shu L, de Havenon A, Liberman A, Henninger N, Goldstein E, Reznik M, Mahta A, Al-Mufti F, Frontera J, Furie K, Yaghi S. Trends in Venous Thromboembolism Readmission Rates after Ischemic Stroke and Intracerebral Hemorrhage. Journal Of Stroke 2023, 25: 151-159. PMID: 36592970, PMCID: PMC9911841, DOI: 10.5853/jos.2022.02215.Peer-Reviewed Original ResearchLonger hospital stayVenous thromboembolismIntracerebral hemorrhageVTE readmissionHospital stayReadmission ratesUtilization Project Nationwide Readmissions DatabaseAcute ischemic stroke hospitalizationsHealth Stroke Scale scoreHistory of VTEVTE risk scoreStroke Scale scoreHigher National InstitutesHigh-risk patientsLife-threatening complicationsNationwide Readmissions DatabasePrincipal discharge diagnosisCox regression modelIschemic stroke hospitalizationsIndex admissionVTE diagnosisVTE prophylaxisVTE ratesVTE riskIschemic stroke
2022
Predictors of Recurrent Venous Thrombosis After Cerebral Venous Thrombosis
Shu L, Bakradze E, Omran SS, Giles J, Amar J, Henninger N, Elnazeir M, Liberman A, Moncrieffe K, Rotblat J, Sharma R, Cheng Y, Zubair AS, Simpkins A, Li G, Kung J, Perez D, Heldner MR, Scutelnic A, von Martial R, Siepen B, Rothstein A, Khazaal O, Do D, Al Kasab S, Rahman LA, Mistry EA, Kerrigan D, Lafever H, Nguyen TN, Klein P, Aparicio HJ, Frontera JA, Kuohn L, Agarwal S, Stretz C, Kala N, ElJamal S, Chang A, Cutting S, Indraswari F, de Havenon A, Muddasani V, Wu T, Wilson D, Nouh A, Asad D, Qureshi A, Moore J, Khatri P, Aziz Y, Casteigne B, Khan M, Cheng Y, Grory BM, Weiss M, Ryan D, Vedovati MC, Paciaroni M, Siegler J, Kamen S, Yu S, Guerrero CL, Atallah E, De Marchis GM, Brehm A, Dittrich T, Psychogios M, Alvarado-Dyer R, Kass-Hout T, Prabhakaran S, Honda T, Liebeskind D, Furie K, Yaghi S. Predictors of Recurrent Venous Thrombosis After Cerebral Venous Thrombosis. Neurology 2022, 99: e2368-e2377. PMID: 36123126, PMCID: PMC9687409, DOI: 10.1212/wnl.0000000000201122.Peer-Reviewed Original ResearchConceptsCerebral venous thrombosisRecurrent venous thrombosisHistory of VTEVenous thrombosisVenous thromboembolismAntiphospholipid antibodiesBlack raceDiagnosis of CVTPositive antiphospholipid antibodiesRecurrent venous thrombosesAntiphospholipid antibody syndromeRecurrent venous thromboembolismCox regression analysisRisk of recurrenceMulticenter international studyAntibody syndromeOral anticoagulationVenous thrombosesConsecutive patientsRare causeMean ageTreatment strategiesThrombosisPatientsSecondary analysisDirect Oral Anticoagulants Versus Vitamin K Antagonists in Cerebral Venous Thrombosis: A Systematic Review and Meta-Analysis
Yaghi S, Saldanha IJ, Misquith C, Zaidat B, Shah A, Joudi K, Persaud B, Khalek F, Shu L, de Havenon A, Mistry EA, Bakradze E, Goldstein ED, Reagan J, Theodorou A, Palaiodimou L, Furie K, Field TS, Tsivgoulis G, Mac Grory B. Direct Oral Anticoagulants Versus Vitamin K Antagonists in Cerebral Venous Thrombosis: A Systematic Review and Meta-Analysis. Stroke 2022, 53: 3014-3024. PMID: 35938419, DOI: 10.1161/strokeaha.122.039579.Peer-Reviewed Original ResearchConceptsCerebral venous thrombosisDirect oral anticoagulantsVitamin K antagonistsVenous thrombosisK antagonistsSystematic reviewRelative riskObservational studyDirect Oral Anticoagulants Versus Vitamin K AntagonistsSafety of DOACsVitamin K antagonist treatmentRecurrent venous thromboembolismHigh-level evidenceLeast moderate riskVenous recanalizationOral anticoagulantsVenous thromboembolismMajor hemorrhageMore patientsAntagonist treatmentIntracranial hemorrhageCombination of keywordsComparable efficacyInclusion criteriaSafety outcomes
2020
Impact of COVID-19 on Outcomes in Ischemic Stroke Patients in the United States
de Havenon A, Ney JP, Callaghan B, Delic A, Hohmann S, Shippey E, Esper GJ, Stulberg E, Tirschwell D, Frontera J, Yaghi S, Anadani M, Majersik JJ. Impact of COVID-19 on Outcomes in Ischemic Stroke Patients in the United States. Journal Of Stroke And Cerebrovascular Diseases 2020, 30: 105535. PMID: 33310595, PMCID: PMC7832426, DOI: 10.1016/j.jstrokecerebrovasdis.2020.105535.Peer-Reviewed Original ResearchConceptsIschemic stroke patientsIschemic strokeFavorable dischargeStroke patientsPrimary analysisLaboratory-confirmed COVID-19COVID-19Vizient Clinical Data BaseAcute coronary syndromeAcute renal failureCohort of patientsCoronavirus disease 2019Clinical data baseCoronary syndromeHospital deathVenous thromboembolismMechanical thrombectomyRenal failureHispanic patientsDischarge diagnosisSubarachnoid hemorrhageWorse outcomesDisease 2019High riskLower odds